MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
20.03
+0.05
+0.25%
After Hours: 20.01 -0.02 -0.10% 16:25 07/26 EDT
OPEN
20.28
PREV CLOSE
19.98
HIGH
20.58
LOW
19.94
VOLUME
973.33K
TURNOVER
0
52 WEEK HIGH
40.16
52 WEEK LOW
19.34
MARKET CAP
932.32M
P/E (TTM)
15.46
1D
5D
1M
3M
1Y
5Y
1D
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Pacira BioSciences, Inc. (NASDAQ:PCRX) has seen a 29% share price drop in the last month. The company's price-to-sales ratio is 1.4x compared to the Pharmaceuticals industry. Pacira Biosciences has been growing revenue less than most other companies recently. Its low P/S ratio is probably due to the company's poor revenue growth prospects. The share price of the company is down 45% in the past month.
Simply Wall St · 3d ago
Weekly Report: what happened at PCRX last week (0715-0719)?
Weekly Report · 4d ago
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary. Small cap stocks are enduring their largest period of underperformance versus large caps to start a year in the last 51 years. Volatility in the Russell 2000 Growth Index was only down 2.9% in the second quarter of 2024.
Seeking Alpha · 07/17 14:40
Weekly Report: what happened at PCRX last week (0708-0712)?
Weekly Report · 07/15 09:10
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
NASDAQ · 07/12 14:41
Pacira BioSciences: Medicare and Medicaid Propose New Reimbursement for Exparel
Dow Jones · 07/10 20:55
CENTERS FOR MEDICARE AND MEDICAID PROPOSE NEW REIMBURSEMENT FOR EXPAREL IN ALL OUTPATIENT SURGICAL ENVIRONMENTS BEGINNING JANUARY 1, 2025
Reuters · 07/10 20:21
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Barchart · 07/10 15:19
More
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Webull offers Pacira Biosciences Inc stock information, including NASDAQ: PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.